Real time people search
Who is

Edward Sapien

AZ, Phoenix, 4613 E Mcneil St, 85044

Pictures(10)

 
 
 
No data available
 
Find hidden profiles and photos for Edward Sapien across MySpace, Facebook and 40+ networks.

Weblinks(4)

SAPIEN Transcatheter Heart Valve - Edwards Lifesciences
CAUTION: Federal (United States) law restricts the Edwards SAPIEN transcatheter heart valve to sale by or on the order of a physician. This device has been ...
SAPIEN Transcatheter Heart Valve - Edwards Lifesciences
SAPIEN Transcatheter Heart Valve ... CAUTION: Federal (United States) law restricts the Edwards SAPIEN transcatheter heart valve to sale by or on the order of ...
Edwards Sapien Transcatheter Heart Valve - YouTube
Oct 7, 2009 ... Juventus vs Shakhtar 1-1 All Goals Full Highlights 10-02-2012 Bonucci 2:19. Watch Later Juventus vs Shakhtar 1-1 All Goals Full Highlights ...
Percutaneous treatment of aortic valve stenosis
The Edwards SAPIEN valve has been deployed with retrograde and transapical .... The Ascendra transapical delivery system for the Edward SAPIEN valve has ...
No data available

Blogs(0)

No data available

Books(0)

No data available

Articles(0)

Documents(4)

Edwards Sapien Facts Sheet - St. Vincent's Heart Valve Clinic
Edwards SAPIEN Transcatheter Aortic Heart Valve. Page 1 of 4. The Edwards SAPIEN valve is a collapsible aortic heart valve that can be introduced into the ...
The Edwards SAPIEN® THV Transcatheter Heart Valve System for ...
Jul 20, 2011 ... The Edwards SAPIEN® THV. Briefing Document – Advisory Committee Meeting. 2. Table of Contents. 1.0. Executive Summary .
The Edwards SAPIEN® THV Transcatheter Heart Valve System for ...
SAPIEN® THV – High Risk Surgical Cohort. Briefing Document – Advisory Committee Meeting. 30April12. CONFIDENTIAL. 1. The Edwards SAPIEN® THV ...
Edwards SAPIEN Transcatheter Aortic Heart Valve - UPMC ...
Nov 2, 2011 ... Fact Sheet: Edwards SAPIEN Transcatheter Aortic Heart Valve. 1 | Page. In November of 2011, the U.S. Food and Drug Administration (FDA) ...
No data available

Faces(0)

 
No data available
No data available
Find hidden profiles and photos for Edward Sapien across MySpace, Facebook and 40+ networks.

Videos(12)

 
 
No data available
 

News(20)

No data available
New heart valve implant procedure may reduce surgery risks
A recent study has claimed that a new minimal invasive procedure in heart valve replacement may help elderly patients who might not survive a standard valve-replacement operation.The device named Sapien, created by Edwards Lifescience Corporation, requires a minimal invasive method where a damaged heart valve is replaced by inserting a catheter through either the femoral artery.
Edwards Valve Win Means First Therapy for Frail Heart Patients
Edwards Lifesciences Corp.s Sapien heart valve may become the first life-saving treatment in the U.S. for frail, elderly patients with diseased valves after a study found it slashed deaths in those with few medical options.
Edwards' Sapien Valve Pumping Up Its Stock
Edwards Lifesciences' recent announcement that it will start selling its groundbreaking replacement heart valve in the U.S. next fall was greeted with much enthusiasm on Wall Street. Shares of the medical device maker shot up 6.7% when the news hit on Dec. 13. The stock rose more than 12% over the next five sessions, briefly touching a record high of 85.47 on Dec. 20. It closed Monday at 80.96. The excitement centers on Edwards' (EW) Sapien aortic
UPDATE 1-Edwards shares soar on heart valve data
* Results for Sapien valve published in medical journal
Edwards Receives Approval to Begin U.S. Clinical Trial of Next-Generation Transcatheter Valve
IRVINE, CA--Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that the U.S. Food and Drug Administration (FDA) conditionally approved the first of two planned cohorts of the randomized, controlled The PARTNER II Trial. Building upon the learnings of the world's first randomized transcatheter heart valve trial -- Edwards' The PARTNER Trial -- the first cohort of The PARTNER II Trial will study the next-generation Edwards SAPIEN XT transcatheter heart valve. This trial includes the low-profile NovaFlex transfemoral delivery system, which broadens the number of eligible patients. This cohort of The PARTNER II Trial will study up to 450 patients with severe, symptomatic aortic stenosis using two-to-one randomization, where for every two patients who receive the Edwards SAPIEN XT valve delivered transfemorally, one will receive standard therapy. The primary endpoint of the trial is a composite of death, major stroke and repeat hospitalization, with secondary endpoints that include valve performance and quality-of-life indicators. Edwards anticipates a second patient cohort for the trial to compare traditional open-heart surgery with the Edwards SAPIEN XT valve delivered either transfemorally or transapically. The Edwards SAPIEN XT valve is commercially available in Europe, where it received a CE Mark in March 2010. The Edwards SAPIEN XT transcatheter valve is an investigational device in the U.S. and not yet available commercially in this country. About Edwards Lifesciences Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," or other similar expressions and include, but are not limited to, the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009. Edwards, Edwards SAPIEN XT and NovaFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo and Edwards SAPIEN are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.
Wells Fargo: Analysts' Upgrades, Downgrades
NEW YORK (TheStreet) -- CHANGE IN RATINGS ATMI upgraded at Citi to Hold from Sell. Wafer starts still about to roll. Price target trimmed to $15 from $18. Ball Corp. upgraded at Goldman to Buy. Company should outperform in a slower growth environment. Crown Holdings upgraded at Goldman to Buy. Company will likely aggressively buy back its stock. Cerner upgraded at Jefferies from Hold to Buy. $87 price target. Stock has pulled back since April and the purchasing environment in improving. Concur Technologies upgraded at Jefferies from Hold to Buy. $55 price target. Corporate travel activity has improved in the past few months. Complete Production Services upgraded at Credit Suisse to Outperform from Neutral on increased earnings outlook, impressive margin growth. Price target jumped to $25 from $19. Cognizant Technology Solutions reinstated at BofA/Merrill with a Neutral rating and 458 price target. Growth potential not mispriced. Eaton upgraded at Wells to Outperform. Estimates also boosted, as the company continues to grow in a slow environment. Eaton estimates, target increased at Morgan Stanley. ETN estimates were raised through 2011. Company is seeing better demand across the board, outside of aerospace. Equal-weight rating and new $83 price target. Human Genome upgraded at Baird from Neutral to Outperform. $32 price target. Stock is down more than 20% this year, even though Benlysta will likely be approved by the FDA later this year. Petrohawk Energy rated new Perform at Oppenheimer. Valuation call, given weak natural gas prices. Owens-Illinois downgraded at Goldman to Neutral. Estimates also cut, because of lower glass volume. Pactiv downgraded at Goldman to Neutral. Valuation call. SEI Investments downgraded at KBW to Market Perform. Management has limited visibility on future growth. Solarwinds downgraded at Jefferies from Buy to Hold. $14 price target. License weakness could continue and the network management market is mature. STOCK COMMENTS / EPS CHANGES Abbott Laboratories estimates upped at Morgan Stanley through 2011. Margins should continue to expand over the coming quarters. Overweight rating and $63 price target. Alliance Data estimates lowered at Goldman through 2012, given the company's new guidance. Neutral rating and $63 price target. AMR estimates, target lowered at UBS. Shares of AMR now seen reaching $14. Estimates also cut, given the company's new guidance. Buy rating. Autozone target upped at Goldman to $211. Industry has pricing power and should benefit from an aging car fleet. Neutral rating. Baidu.com estimates, target boosted at Goldman. Shares of BIDU now seen reaching $90. Estimates also upped, given a higher customer count. Buy rating. CA Inc price target cut at Credit Suisse to $20 from $22. Large bookings miss in 1Q results. Maintain Neutral rating. Cephalon estimates, target raised at Goldman. Shares of CEPH now seen reaching $68. Estimates also increased, to match the company's new guidance. Neutral rating. CF industries price target higher at BofA/Merrill. CF price target raised to $94 from $85. Expecting positive 2Q10 results. Maintain Buy rating. Comerica estimates, target upped at UBS. Shares of CMA now seen reaching $28. Estimates also boosted, given the company's improved credit outlook. Sell rating. EMC price target higher at Citi. EMC price target raised by a dollar to $25. Selloff on modest 2010 beat represents buying opportunity. Maintain Buy rating. Edwards Lifesciences estimates upped at Morgan Stanley through 2012. Company should have a positive launch for Sapien. Equal-weight rating. F5 Networks price target boosted at Citi to $83 from $78. Another substantial beat and raise 2Q. Maintain Hold rating. F5 Networks estimates, target raised at UBS. Shares of FFIV now seen reaching $83. Estimates also increased, as the company is posting solid growth and seeing record margins. Neutral rating. Greenhill estimates, target cut at Goldman. GHL estimates were reduced through 2012. Company is seeing lower advisory fees. Neutral rating and new $65 price target. Coca-Cola price target higher at BofA/Merrill. KO price target raised by a dollar to $63. 2Q volumes (+5%), margins (+210bps) better than forecasted. Maintain Buy rating. Linear Technology estimates increased at UBS through 2012. Company continues to perform well, despite a murky macro outlook. Neutral rating and new $31 price target. Manpower target, estimates boosted at Barclays. MAN price target raised by a dollar to $62. Robust 2Q performance and strong 3Q guidance. 2010 and 2011 EPS estimates lifted to $1.35 and $2.58, respectively. Maintain Overweight rating. MKS Instruments estimates increased at Goldman through 2012. Company is realizing better operating leverage. Neutral rating and $23 price target. Altria estimates boosted at BofA/Merrill. 2010, 2011, 2012 EPS estimates increased to $1.90, $2.03, $2.16, respectively. 2Q results showed tobacco momentum and execution. Maintain Buy and $24 price target. Altria estimates, target raised at Morgan Stanley. Shares of MO now seen reaching $22. Estimates also increased, given the better pricing and volume outlook. Equal-weight rating. Morgan Stanley numbers changed at Barclays. MS 2010 EPS estimates raised to $2.97, 2011 cut to $3.15. MS benefitted from agency business model. Maintain $34 price target and Equal Weight rating. M&T Bank estimates, target boosted at UBS. Shares of MTB now seen reaching $89. Estimates also upped, given the company's improved credit quality. Neutral rating. Netflix target, estimates boosted at Credit Suisse. NFLX price target surged to $90 from $31 after 2Q10 revenue and EPS beat. 2010 and 2011 EPS estimates jumped to $2.82 and $3.69, respectively. Maintain Underperform rating. Netflix estimates, target raised at Oppenheimer. Shares of NFLX now seen reaching $110. Estimates also increased, given increased streaming usage and international expansion. Underperform rating. Qualcomm estimates, target raised at Goldman. Shares of QCOM now seen reaching $44. Estimates also increased, given continued smartphone growth. Buy rating. Qualcomm estimates, target lowered at UBS. Shares of QCOM now seen reaching $45. Estimates also cut, given the company's lower margins. Buy rating. Qualcomm estimates raised at Credit Suisse. QCOM 2010, 2011, 2012 EPS estimates increased to $2.33, $2.39, $2.50, respectively. Mixed 3Q results but CDMA/WCDMA market still seeing robust growth. Neutral rating and $40 price target. Robert Half target, estimates higher at BofA/Merrill. RHI price target lifted to $25 from $23 on strong 2Q10 results. 2010 and 2011 EPs estimates raised to 40 cents and 86 cents, respectively. Underperform rating. RLI estimates increased at Oppenheimer through 2011. Company has strong earnings momentum. Perform rating. Starbucks price target trimmed at Barclays to $26 from $28 on lower than expected 2011 estimates. 2010 and 2011 EPS estimate dropped to $1.23 and $1.40, respectively. Reiterate Equal Weight rating. Textron estimates, target upped at Goldman. TXT estimates were boosted through 2012. Company is seeing solid growth, outside of Cessna. Buy rating and new $25 price target. US Bancorp estimates, target reduced at Morgan Stanley. Shares of USB now seen reaching $29. Estimates also cut, given higher legislative costs. Equal-weight rating. Western Digital numbers lowered at UBS. WDC estimates were cut through 2012. Company is seeing margin contraction, though further downside could be limited. Buy rating and new $34 price target. Wells Fargo 2010 estimate raised at Barclays to $2.20 on strong 2Q10 performance. 2011 EPS estimate set at $3.00. Maintain Overweight rating and $36 price target. Xilinx estimates, target boosted at UBS. Shares of XLNX now seen reaching $35. Estimates also upped, given the company's secular growth trends. Buy rating.
Ann Coulter Tells It Like It Is About Patty Murray | RegularGuyRant.com
One of my favorite writers happens to be the one and only, Queen of Conservatism: Ann Coulter. Coulter’s latest article is hilarious, but it is also fact filled and should be a warning to the voters in Washington State. Another vote for Senator Patty Murray is a vote for someone without a clue. I noted on this blog recently Patty’s habit of putting her foot in her mouth. I’ve heard rumors she is suffering from a case of Biden, but I think the reality is that she’s simply out of touch. She’s operating on Planet Liberal, while most of us are still right here on the good ol’ Earth. From Ann Coulter’s column (Titled: “The Stupidest Person In America”): With amazing understatement, one of Murray's Democratic colleagues in the state senate told The Seattle Times in 1992: She just doesn't strike you as somebody who's been reading The New York Times every day for the past five years. I wonder when Katie Couric is going to ask Murray what newspapers she reads. After Murray was elected to the U.S. Senate, the Democrats tried to keep her locked in her office to prevent her from saying anything that might end up in a newspaper. But in the confusion after the 9/11 attack, the leadership must have lost the keys and Murray escaped to say this about Osama bin Laden: He's been out in these countries for decades, building schools, building roads, building infrastructure, building day-care facilities, building health-care facilities, and the people are extremely grateful. He's made their lives better. Yes, Osama was out building day-care facilities -- and probably sponsoring Bring Your Daughter to Work days! I defy anyone to produce something stupider ever uttered by a homo sapiens. Not Barbara Boxer, Joe Biden or even John Edwards can hold their dimly lit candles to her. Murray, whose college major was recreation, got her start in politics fighting to save her own useless government job. The laughably apocryphal story she tells is that she was told by some crusty ol
Providence Health Care: Heart Valve Provides Life-Saving Alternative to Open-Heart Surgery
Marketwire VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 23, 2010) - According tooi/full/10.1056/NEJMoa1008232">recent study result published in the New England Journal of Medicine (NEJM), a new aortic heart valve replacement procedure, called transcatheter aortic-valve implantation (TAVI) has shown to be a viable life-saving option for patients who are unable to undergo open heart surgery. The study, which is part of the Partner Trial (Placement of AoRTic TraNscathetER Valve), compared the health outcomes of patients who underwent TAVI using the investigational Edwards SAPIEN transcatheter valve to those who received standard therapy. All patients in the study had severe aortic stenosis and were considered not to be suitable candidates for surgery. The conclusions stated that TAVI, as compared with standard therapy, significantly reduced the rates of death for these patients. Severe aortic stenosis is a progressive and life-threatening disease, and patients who do not undergo surgical valve replacement of their diseased aortic valve have no effective treatment option to prevent or delay their disease progression. Without treatment, previous studies indicate 50 per cent of patients will not survive more than two to three years. Heart valve replacement surgery usually requires a long incision in the centre of the chest to enable surgeons to expose the heart, which is temporarily stopped while the valve is replaced and sutured in place. A heart-lung bypass machine is used to keep the patient's blood circulating until the heart function is restored. Using the TAVI procedure, the Edwards SAPIEN valve (a collapsible aortic heart valve) can be inserted in two ways: through a small incision in the ribs (transapical) orthreaded up to the patient's heart through the circulatory system using a catheter inserted in the patient's groin (transfemoral). The NEJM study focused on the transfemoral procedure. In 2005 a team of specialists at the Heart Centre in St. Paul's Hospital, Vancouver, BC (one of the partner sites in the trial) and University of British Columbia, were the first world's first to successfully perform transarterial procedures (pioneered by the St. Paul's Heart Centre team) and the world's first to successfully perform a transapical aortic valve replacement. The Heart Centre began with 17 procedures in 2005 and have now done over 200 transfemoral procedures and over 150 transapical. The team has also trained over 50 other programs around the world, with over 10,000 procedures now done worldwide. "The world-renowned research and clinical innovation in the Heart Centre at St. Paul's Hospital continue to position British Columbia as a leader in cardiac sciences," says Hon. Kevin Falcon, Minister of Health Services. "The research and cardiac services at St. Paul's have a rich 50-year history of excellence, and I'm confident this tradition and breakthrough improvements to patient care -- will continue through St. Paul's Hospital's leading contributions and collaborations with BC's health authorities, Cardiac Services BC, universities and other research partners." St. Paul's world-renowned interventional cardiologist, Dr. John Webb is co-author of the study and a member of the executive committee for the trial's design. He was also the first interventional cardiologist in North America to perform a successful percutaneous aortic valve replacement. "The results from the trial to date are very encouraging," says Dr. Webb, McLeod Family Professor in Valvular Heart Disease Intervention at the University of British Columbia. "We hope that this will eventually become a standard treatment option. Not only is it less invasive than traditional open-heart surgery, but this procedure provides patients who are not candidates for surgery with an option that has so far proven to have better health outcomes than standard treatment." AtSt. Paul's Hospital, the procedure is currently provided on compassionate grounds for patients who are too frail to survive open-heart valve replacement surgery. These findings were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium held in Washington, DC, this week. About Providence Health Care Providence Health Care is one of Canada's largest faith-based health care organizations, operating 14 health care facilities in Greater Vancouver. Guided by the principle "How you want to be treated", PHC's 1,200 physicians, 6,000 staff and 1,500 volunteers deliver compassionate care to patients and residents in British Columbia. The organization's $655-million budget covers 646 acute care beds, 700 continuing care beds, 76 rehabilitation beds, and 12 hospice beds. PHC operates one of two adult academic health science centres in the province, performs cutting-edge research in more than 30 clinical specialties, and focuses its services on six "populations of emphasis": cardio-pulmonary risks and illnesses, HIV/AIDS, mental health, renal risks and illness, specialized needs in aging and urban health. www.providencehealthcare.org. Note to editors/reporters - the following are available upon request: Interviews with cardiac experts involved with the trial Interviews with transcatheter aortic valve implant patient Fact sheets on the Partner trial, Edwards Sapien Valve, Aortic Stenosis at www.heartandlung.ca/partner Various images of Edwards Sapien valve, aortic stenosis Videos: - Transfemoral Animation - Deployment of the Edwards SAPIEN valve - Cath Lab Footage
F.D.A. Approves Less Invasive Heart Valve Replacement
The Sapien, made by Edwards Lifesciences, offers an option for patients who are too old or frail for the current procedure.
Inaugural humor fest takes international flair seriously
A short man in a sports jacket stood at the microphone, arguing with his larger, more gruff companion last night at Cambridge College. It was a comic set-up straight out of vaudeville, as familiar as Abbott and Costello. Except the act, Duo Humor Sapiens, was done entirely in Spanish with a backdrop of caricatures of the late Senator Edward Kennedy, ...
Edwards Reaffirmed at Neutral - Analyst Blog
The development of Sapien products holds immense potential for Edwards as it provides surgeons the option to eliminate the possibility of open heart procedures. The company has the first mover advantage in the US with its recent launch of Sapien ...
CE Mark for Edwards' Intuity - Analyst Blog
Current investor focus primarily lies on the uptake of Edwards’ Sapien THV that received approval in US in November 2011. The company also expects approval for the Cohort A population in the second quarter, which will be preceded by an FDA advisory panel.
For frail patients, new heart valve has value
This month, doctors at Riverside Methodist Hospital were the first in central Ohio to use the technology, which is called the Edwards SAPIEN Transcatheter Heart Valve and is made by Edwards Lifesciences. Riverside and Ohio State University’s ...
Edwards Reaffirmed at Neutral
Edwards was adversely affected by economic pressure in southern ... Meanwhile, current investor focus remains on the potential US approval of Sapien THV for Cohort A patients. A higher rate of stroke in patients undergoing TAVR evokes concern.
Women fare better than men after TAVI
Edwards Sapien and Sapien XT, Edwards Lifesciences; CoreValve, Medtronic) through the subclavian, transapical or transfemoral route. Patients were enrolled in the study if they had a logistic EuroSCORE of more than 20% or if surgery was deemed high risk.
CE Mark for Edwards' Intuity
Current investor focus primarily lies on the uptake of Edwards’ Sapien THV that received approval in US in November 2011. The company also expects approval for the Cohort A population in the second quarter, which will be preceded by an FDA ...
Lehigh Valley Hospital cleared for 'transformative' heart procedure
A deliberate approach Because of the risks, the FDA allows Sapien implants only for patients ineligible for open-heart surgery. And Edwards Lifesciences, the Irvine, Calif.-based maker of the valve, has given it a slow, deliberate introduction.
Hastings man benefits from new heart procedure
The Edwards SAPIEN Transcatheter Heart Valve allows physicians to repair faulty aortic valves without having to do open-heart surgery. The device is meant for people suffering from aortic stenosis, in which the aortic valve that controls blood flow out of ...
U-M Cardiovascular Center now offers Edwards aortic valve replacement
University of Michigan Cardiovascular Center surgeons and interventional cardiologist are working together to offer patients comprehensive options to treat aortic stenosis with the new FDA-approved Edwards SAPIEN Heart Valve and through a ...
Hastings man first in state to undergo heart procedure
“A person is always concerned about heart surgery, but it went very well.” Kimminau underwent the Edwards SAPIEN Transcatheter Heart Valve procedure Dec. 14. Although he recovered from the procedure within a week, he remained in the hospital because of ...
No data available
No data available
No data available
No data available
No data available

Related people(15)

A Sapien Merced CA 95340
A Sapien Grand Blanc MI 48439
A Sapien El Paso TX 79938
A Sapien Canutillo TX 79835
A Sapien Canutillo TX 79835
Aaron Sapien Las Cruces NM 88001
Aaron Sapien Seguin TX 78155
Aaron Sapien Seguin TX 78155
Adela R Sapien Gardena CA 90247
Adella Sapien Gardena CA 90247
Adrian Sapien El Paso TX 79928
Adrian Sapien El Paso TX 79928
Adriana Sapien Oxnard CA 93036
Adriana Sapien El Paso TX 79936
Adrianna Sapien Itasca IL 60143

Microblogs(3)

 
 
Loading...

Biography(10)

No data available
Neanderthal
alternatively as a subspecies of Homo sapiens (Homo sapiens ... Edward Rubin of the Lawrence Berkeley National Laboratory states recent ...
King Edward VI Grammar School (Chelmsford)
dms | motto Quicquid agas sapiens age fortiter ex animoque ... id 20 | title King Edward VI Grammar School, Chelmsford » 'The Chelmsfordian | ...
Origin of language
Archaic Homo sapiens: Archaic Homo sapiens. Steven Mithen proposed the term Hmmmmm for the pre- ... References: Vajda, Edward. http://pandora. ...
Carl Linnaeus
REDIRECT MediaWiki talk:Carolus Linnaeus.
Anthropology
Anthropologists study topics including Homo sapiens origin and ... Edward Sapir: Anthropologists were recruited from England and the USA, setting ...
System of systems
Curry, Edward. 2012. http://www. edwardcurry. ... External links : http://www. youtube. ... http://sapiens. revues. org/index1011. html Parker, J ...
Hellboy Universe
Abe Sapien: The first spin-off from Hellboy, centred around Abraham Sapien , beginning with Drums of the Dead (4 ... Sir Edward Grey, Witchfinder ...
Wicked Wanda
Homer Sapiens and J. Hoover Grud ... Liberace , Howard Hughes , Harold Wilson , Edward Heath , Ronald Reagan , Kirk Douglas , Idi Amin , ...
QI (H series)
sapiens its nomenclature, so it was felt the honour should go to him. The next aspirant, American paleontologist Edward Drinker Cope , ...
Decimation (comics)
Jennifer, Malcolm, Edward "Ned" and Nell Hardy | Revealed in New Excalibur 6. ... Homo mermanus vs Homo sapiens superior: One of the reasons ...